Results for В сравнение с translation from Bulgarian to English

в сравнение с предишните
compared to historical controls.

В сравнение с пациенти с
renal impairment pharmacokinetic parameters of tenofovir were determined following administration of a single dose of tenofovir disoproxil 245 mg to 40 non-hiv, non-hbv infected patients with varying degrees of renal impairment defined according to baseline creatinine clearance (crcl) (normal renal function when crcl > 80 ml/ min; mild with crcl = 50-79 ml/ min; moderate with crcl = 30-49 ml/ min and severe with crcl = 10-29 ml/ min).

p стойност (в сравнение с
p value (vs aripiprazole)

в сравнение с предишните контроли
1.28 compared to historical controls.

седмици в сравнение с плацебо.
and crp (mg/ dl) values) improved at 24 or 26 weeks compared to placebo.

Невирапин: в сравнение с предишните
nevirapine: compared to historical controls, levels appeared to be unchanged.

Промени в сравнение с 2013 г.
changes to 2013

5p=0,0157 в сравнение с плацебо.
5 p=0.0157 compared to placebo.

в сравнение с групата за наблюдение
p-value vs observation

В сравнение с вориконазол 200 mg ДД,
compared to voriconazole 200 mg bid,

трансплантацията (43% в сравнение с 28%).
ori (43% as compared with 28%).

в сравнение с нивата от 1990 г.
compared to 1990 levels

2 p<0,0001 в сравнение с плацебо.
2 p< 0.0001 compared to placebo.

Въздействие в сравнение с базовия сценарий
impact against baseline scenario

адалимумаб в сравнение с плацебо групата.
61 trudexa 80/ 40 mg and 160/ 80 mg compared to placebo and was seen at weeks 26 and 56 in charm as well among the adalimumab treatment groups compared to the placebo group.

(в сравнение с нивото от 1990 г.)
(compared to 1990 levels)

Брой приети доклади в сравнение с плана
number of reports adopted compared to planned adoptions

адалимумаб в сравнение с плацебо групата. о
82 trudexa 80/ 40 mg and 160/ 80 mg compared to placebo and was seen at weeks 26 and 56 in charm as well among the adalimumab treatment groups compared to the placebo group.

Повторно използване в сравнение с продължаващо използване
reuse versus continued use

т ефикасност в сравнение с монотерапията с viraferon.
the increased response rate to the combination of viraferon + ribavirin, compared with viraferon alone, is maintained across all subgroups.